Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bioverativ Therapeutics Inc.
With
Swedish Orphan Biovitrum
Participants are assigned to one of three treatment regimens: 1) a tailored prophylaxis regimen, 2) a weekly dosing regimen, or 3) an on-demand regimen. Treatment continued for 28 (±2) to 52 (±2) weeks. PK assessments for all participants are conducted on varying schedules, according to participants' group assignments. Additionally, two subgroups are defined. One subgroup of participants undergo PK profiling with a single dose of the comparator Advate®. A second subgroup consists of participants from any of the treatment arms that required surgery during the study. Depending upon country location, participants might have the option of continuing treatment within study 8HA01EXT (NCT01454739).
Age
12–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male, ≥12 years of age with weight at least 40 kg
Diagnosed with severe hemophilia A, defined as \<1 IU/dL (\<1%) endogenous Factor VIII)
History of at least 150 documented prior exposure days to any Factor VIII product
Platelet count ≥100,000 cells/μL
You may not be if
History of Factor VIII inhibitors
Kidney and liver dysfunction
Diagnosed with other coagulation disorder(s) in addition to hemophilia A
Prior history of hypersensitivity or anaphylaxis associated with any FVIII or IV immunoglobulin administration